Table 1.
Cytotoxicity against human cancer cell lines.
| Compound | IC50 (µM) ± SD | |||||||
|---|---|---|---|---|---|---|---|---|
| PSN1 | 2008 | C13* | LoVo | A431 | BxPC3 | HCT-15 | BCPAP | |
| 1 | 0.42 ± 0.1 | 0.31 ± 0.1 | 0.28 ± 0.1 | 0.98 ± 0.1 | 0.41 ± 0.1 | 1.74 ± 0.5 | 0.39 ± 0.1 | 0.51 ± 0.2 |
| Chlorambucil | >100 | 34.58 ± 16.5 | >100 | >100 | 74.48 ± 8.2 | >100 | 44.52 ± 9.5 | >100 |
| CDDP | 18.11 ± 3.2 | 2.18 ± 0.9 | 22.11 ± 3.2 | 9.15 ± 2.1 | 2.21 ± 0.4 | 7.22 ± 2.2 | 15.28 ± 2.6 | 7.31 ± 1.2 |
CDDP: cisplatin, SD = standard deviation. Cells (3–5 × 104·mL−1) were treated for 72 h with different concentrations of tested compounds. Cytotoxicity was assessed using the MTT test. IC50 values were calculated using a four-parameter logistic model (p < 0.05).